FDA Greenlights First Novel ADHD Medication in Over 20 Years --- Simtriyo

Buzzline

The FDA has granted approval for Simtriyo (centanafadine), marking the inaugural endorsement of a norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) for ADHD, developed by Otsuka Pharmaceutical. This once-daily extended-release capsule is authorized for use in both adults and children aged 6 and older, who weigh at least 44 pounds, providing a fresh treatment alternative for approximately 22.5 million individuals in the U.S. with ADHD. Unlike traditional stimulants that primarily influence dopamine and norepinephrine, Simtriyo's unique mechanism that involves three transporters also regulates serotonin. Phase 3 clinical trials demonstrated improvements beyond the primary symptoms, including enhanced executive functioning and emotional regulation. The medication comes with boxed warnings that necessitate vigilance for suicidal thoughts in younger patients and assessments to prevent misuse. It is anticipated to be commercially available in late 2026, subject to final classification by the DEA. Disclosure: This video contains stock footage and content created or enhanced using AI-assisted tools.  ai-generated

Transcript

00:00For the first time in over two decades, the FDA has approved a genuinely new way to treat ADHD.

00:06The drug is called Simtrio, and it just became the first-ever triple reuptake inhibitor cleared

00:11for the condition, acting on three brain chemicals at once—dopamine, norepinephrine,

00:17and serotonin. That third target is what makes this different. Every stimulant on the market

00:22today focuses mainly on dopamine and norepinephrine. Simtrio's developer, Otsuka Pharmaceutical,

00:28says adding serotonin regulation helped patients in clinical trials with more than just focus.

00:35It improved emotional control and executive function, too. The approval covers adults and

00:40children as young as six who weigh at least 44 pounds, opening a new option for roughly 22.5

00:47million Americans living with ADHD, many of whom stop taking their current medication because of

00:53side effects or because it simply stops working. The drug does carry boxed warnings.

00:58Doctors must monitor pediatric patients for suicidal thoughts. And because it's a CNS stimulant,

01:05it still needs a final scheduling decision from the DEA before it hits pharmacy shelves.

01:11Otsuka expects Simtrio to be commercially available later this year. For the ADHD community,

01:17doctors are calling this the biggest treatment shakeup since the early 2000s.

01:21Disclosure. This video contains stock footage and content created or enhanced using AI-assisted tools.

Category

Transcript

Comments

Recommended